Your Global Leader in Stem Cell Market Research
In 2006, Shinya Yamanaka and Kazutoshi Takahashi reported the Nobel Prize winning discovery of induced pluripotent stem cells (iPSCs) in Cell, forever changing the landscape of stem cell research.  In the 10 years that have since passed, iPSC technology has advanced the fields of drug discovery, toxicology, disease modelling, and cellular medicine.
To celebrate and honor these achievements, this article highlights the the most epic iPSC advances of all time. [Read more…]
NEW YORK, Oct. 30, 2017 — Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech, Inc. (NASDAQ:FBIO) company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, announced today that it has entered into a lease agreement with the UMass Medicine Science Park in Worcester, Massachusetts, for a manufacturing facility to support the clinical development and commercialization of the Company’s CAR T product candidates.
The facility is expected to be operational for the production of personalized CAR T therapies in 2018. Mustang anticipates initially building cell-processing capabilities to support its lead CAR T product candidates MB-101 in glioblastoma, and MB-102 in acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. [Read more…]
Biostage is a clinical-stage company specializing in bioengineered organ implants to treat cancer and other conditions involving the esophagus, bronchus and trachea. In August 2017, Biostage transplanted its esophageal implant product into its first patient worldwide, a 75-year old man with cancer. On the heels of this historic accomplishment, I am pleased to share this interview with Jim McGorry, President and CEO at Biostage, Inc. In this interview, we discuss the company’s vision, its research partnerships, clinical trial strategy, and five-year goals.
Please note that this interview was conducted prior to Biostage’s breach and failure to fund by First Pecos.
Read on to learn more about how Biostage is introducing bioengineered organ implants to the regenerative medicine landscape. [Read more…]
Dental pulp is the soft living tissue inside a tooth that contains mesenchymal stem cells (MSCs). Â The ideal time to harvest dental stem cells is when children lose their deciduous (baby) teeth, either through natural loss or extraction.
An important way to gauge innovation and progress within the dental stem cell market is to consider trend rate data for scientific publications over a trailing ten-year period.
PubMed is a service of the U.S. National Library of Medicine and the National Institutes of Health (NIH) that contains citations from MEDLINE and a collection of other life science journals.
The data presented below was generated using the PubMed database, because it is the largest, most comprehensive, and most up-to-date resource aggregating scientific publications worldwide.
It is also the most versatile tool for screening by multiple criteria. [Read more…]
When parents have twins, they often choose to bank the cord blood of both twins for a variety of reasons. Genetic disorders can emerge in fraternal twins due to the contrasts in their genetic makeups and in both fraternal and identical twins because of environmental factors and epigenetics.1,2,3 For some blood and immune disorders, it may be better to use one twin’s stem cells to treat the other twin’s disease, especially because twins are more likely to be a strong HLA match for each other.
In this article:
Umbilical cord blood banking is the collection and storage of the blood contained within the umbilical cord of a newborn for future medical use. With multiple births, storing the cord blood from two or more babies increases the total amount of cord blood stored, making multiple doses available to the family if needed.
